Bromide

Bromide

SCHEMBL220276

[Br-].[Zn+]c1ccccn1

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1018196 0.97
Iodide SCHEMBL2988326 0.94
Tetrahydrofuran SCHEMBL6005004 0.82 KDM4E (0.34)
Dipyridyl SCHEMBL28857337 0.67 KDM4E (0.88)
Dipyridyl SCHEMBL2250385 0.67 KDM4E (0.88)
Dipyridyl SCHEMBL29768749 0.67 KDM4E (0.88)
Dipyridyl SCHEMBL8687972 0.67 KDM4E (0.88)
Dipyridyl SCHEMBL3751791 0.67 KDM4E (0.88)
Dipyridyl SCHEMBL196501 0.67 KDM4E (0.88)
Dipyridyl SCHEMBL30451264 0.67 KDM4E (0.88)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 744 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 WO claimed
US-20260132139-A1 HIV INHIBITOR COMPOUNDS GILEAD SCIENCES INC (US) 2026-05-14 US disclosed
CN-122010905-A Pyrazolyl derivatives as anticancer agents 诺华股份有限公司 2026-05-12 CN disclosed
US-20260123269-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-04-30 US disclosed
EP-4692076-A1 HIV INHIBITOR COMPOUNDS Gilead Sciences, Inc. (US) 2026-02-11 EP disclosed
EP-4344702-B1 PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS NOVARTIS AG (CH) 2026-01-28 EP disclosed
US-20260006982-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-01-01 US disclosed
WO-2025242747-A1 MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS MERCK PATENT GMBH (DE) 2025-11-27 WO disclosed
US-12479853-B2 HIV inhibitor compounds GILEAD SCIENCES, INC. (US) 2025-11-25 US disclosed
US-20250359473-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERAL DISPLAY CORPORATION (US) 2025-11-20 US disclosed
US-6169184-B1 REACTING SUBSTITUTED PYRIDINE WITH SPECIFIED ARYL COMPOUND BASF AKTIENGESELLSCHAFT (DE) 2001-01-02 US disclosed
WO-2000039118-A1 AROMATIC AMIDES ELI LILLY AND COMPANY (US) 2000-07-06 WO disclosed
EP-0998285-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2000-05-10 EP disclosed
WO-2000021663-A2 POLYMER-SUPPORTED PHOSPHORUS LIGANDS FOR CATALYSIS E.I. DU PONT DE NEMOURS AND COMPANY (US) 2000-04-20 WO disclosed
US-6037354-A ADMINISTERING PHENYL-SUBSTITUTED THIAZOLIDIN-4-ONE OR OXAZOLIDIN-2-ONE DERIVATIVE TO TREAT BENIGN PROSTATE HYPERPLASIA; SIDE EFFECT REDUCTION MERCK & CO., INC. (US) 2000-03-14 US disclosed
CN-1230181-A Process for preparing substituted phenylpyridines BASF AG (DE) 1999-09-29 CN disclosed
EP-0891356-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE Merck & Co., Inc. (US) 1999-01-20 EP disclosed
US-5854265-A Biheteroaryl inhibitors of farnesyl-protein transferase MERCK & CO., INC. (US) 1998-12-29 US disclosed
WO-1998057641-A1 ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1998-12-23 WO disclosed
WO-1997036897-A1 INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE MERCK & CO., INC. (US) 1997-10-09 WO disclosed